LEADER 04909nam 22006255 450 001 9910409705303321 005 20220701110326.0 010 $a981-15-3266-4 024 7 $a10.1007/978-981-15-3266-5 035 $a(CKB)4100000010672719 035 $a(DE-He213)978-981-15-3266-5 035 $a(MiAaPQ)EBC6138211 035 $a(PPN)243229496 035 $a(EXLCZ)994100000010672719 100 $a20200317d2020 u| 0 101 0 $aeng 135 $aurnn#008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRegulation of Cancer Immune Checkpoints $eMolecular and Cellular Mechanisms and Therapy /$fedited by Jie Xu 205 $a1st ed. 2020. 210 1$aSingapore :$cSpringer Singapore :$cImprint: Springer,$d2020. 215 $a1 online resource (X, 653 p. 105 illus., 57 illus. in color.) 225 1 $aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v1248 311 $a981-15-3265-6 327 $aIntroduction -- Molecular and cellular functions of CTLA-4 pathway -- Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond -- Discovery of new immune checkpoints: family grows up -- Mechanisms of resistance to checkpoint blockade therapy -- Molecular events behind adverse effects -- Rational discovery of response biomarkers -- Spatiotemporal changes in checkpoint molecule expression -- Functions of checkpoint molecules beyond immune evasion -- Genetic alterations and checkpoint expression -- Regulations on messenger RNA: wires and nodes -- Folded or degraded in endoplasmic reticulum -- Mono- and poly-ubiquitination: tags for fates -- Lysosome as the black hole for checkpoint molecules -- Phosphorylation: a fast switch for checkpoint signalling -- Palmitoylation as a signal for delivery -- Checkpoints under traffic control: from and to organelles -- Exosome and secretion: action on? -- Macromolecules and antibody-based drugs -- Mechanisms inspired targeting peptides -- Small molecular inhibitors -- Therapeutic development of immune checkpoint blockers -- Concluding remarks. 330 $aThis book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies. 410 0$aAdvances in Experimental Medicine and Biology,$x0065-2598 ;$v1248 606 $aCancer$xResearch 606 $aImmunology 606 $aMolecular biology 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000 606 $aMolecular Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/B1700X 606 $aCāncer$2thub 606 $aImmunitat cel·lular$2thub 608 $aLlibres electrōnics$2thub 615 0$aCancer$xResearch. 615 0$aImmunology. 615 0$aMolecular biology. 615 14$aCancer Research. 615 24$aImmunology. 615 24$aMolecular Medicine. 615 7$aCāncer 615 7$aImmunitat cel·lular 676 $a616.994079 702 $aXu$b Jie$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910409705303321 996 $aRegulation of Cancer Immune Checkpoints$92139484 997 $aUNINA